New Releases from NCBI BookshelfRavulizumab (Ultomiris): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with anti–aquaporin 4 (AQP4) antibody–positive neuromyelitis optica spectrum disorder (NMOSD) [Internet].Ravulizumab (Ultomiris): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with anti–aquaporin 4 (AQP4) antibody–positive neuromyelitis optica spectrum disorder (NMOSD) [Internet].
CADTH recommends that Ultomiris be reimbursed by public drug plans for the treatment of neuromyelitis optica spectrum disorder (NMOSD) if […]
